Skip to main content
European Medicines Agency's logo Go to homepage

Main navigation

  • Medicines
    • Find medicine
    • Therapeutic areas: latest updates
    • Download medicine data
    • What we publish on medicines and when
    • Medicines under evaluation
    • National registers
  • Human regulatory
    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
    • Medical devices
    • Herbal products
  • Veterinary regulatory
    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
  • Committees
    • Overview
    • How the committees work
    • CHMP
    • CVMP
    • PRAC
    • COMP
    • HMPC
    • CAT
    • PDCO
    • Working parties and other groups
  • News & events
    • Overview
    • News
    • Events
    • What's new
    • Committee highlights
    • Publications
    • Press and social media
    • Open consultations
    • RSS feeds
  • Partners & networks
    • Overview
    • EU partners
    • International activities
    • Patients and consumers
    • Healthcare professionals
    • Pharmaceutical industry
    • Networks
    • Health technology assessment bodies
  • About us
    • Overview
    • What we do
    • Who we are
    • How we work
    • Fees
    • Support to SMEs
    • Annual reports and work programmes
    • History of EMA
    • Careers
    • Procurement
    • Glossaries
    • About this website
    • Data protection and privacy
    • Contacts
  1. Home
  2. Medicines
  3. NovoSeven - withdrawal of application for variation to marketing authorisation

NovoSeven - withdrawal of application for variation to marketing authorisation

Application withdrawn

The application for a change to this medicine's authorisation has been withdrawn.

eptacog alfa (activated)
Post-authorisationHuman

Page contents

  • Overview
  • Key facts
  • Documents
  • Related information on withdrawals
  • News on NovoSeven
  • More information on NovoSeven

Overview

On 3 April 2006, Novo Nordisk A/S has officially notified the Committee for Medicinal Products for Human Use (CHMP) that they wish to withdraw their application for a new indication for NovoSeven, in the treatment of acute intracerebral haemorrhage (ICH) in adults for limiting haemorrhage growth and improving clinical outcome.

NovoSeven is a powder and solvent for injection that contains the active substance eptacog alfa (activated human recombinant coagulation factor VII). NovoSeven has been approved in the European Union since 1996.

NovoSeven is currently used for the treatment and prevention of bleeding connected with surgery in patients with haemophilia who have developed 'inhibitors' (antibodies) to factor VIII or IX. It is also used in patients with acquired haemophilia, in patients with congenital factor VII deficiency, and in patients with Glanzmann's thrombasthenia (a rare bleeding disorder) who cannot be treated by a transfusion of platelets.

NovoSeven was to be used to treat adult patients with intracerebral haemorrhage (bleeding inside the brain). NovoSeven was expected to limit the bleeding, and so reduce the consequences of the intracerebral haemorrhage.

NovoSeven contains eptacog alfa (activated), which is a blood coagulation factor protein. In the body, eptacog alfa acts like one of the substances involved in blood coagulation (clotting), Factor VII. It increases the production of thrombin, another coagulation factor, on the surface of the particles that make up blood clots (the platelets), and this helps producing a stable 'plug' at the site of bleeding. In intracerebral haemorrhage, NovoSeven is expected to slow down the bleeding and the spread of the haemorrhage, thus improving the outcome for the patient.

The Company submitted the results of three studies, involving a total of 486 patients. The main study was carried out in 399 patients (aged 66 on average), and compared the effectiveness of three dosages of NovoSeven to that of a placebo (dummy treatment). The effectiveness of NovoSeven was assessed by looking at its effect on the volume of the haemorrhage inside the brain, measured using a scan (percentage change in the volume after 24 hours of treatment with NovoSeven or placebo).

The application was at Day 157 when the company withdrew it. The CHMP normally takes up to 90 days (with the possibility to extend it to another 90 days) to adopt an opinion after it has received an application for a change to a marketing authorisation. Following CHMP opinion, it usually takes around 6 weeks for the European Commission to update the licence.

Based on the review of the data and the company's response to the CHMP list of questions, at the time of the withdrawal, the CHMP had concerns and was of the provisional opinion that NovoSeven could not be approved for the treatment of acute intracerebral haemorrhage.

The main concern of the CHMP was that the data were too limited to evaluate the benefit and the potential risks of NovoSeven in intracerebral haemorrhage. The data submitted show that NovoSeven has an effect on the volume of the haemorrhage, but it is not clear how this effect translates into a better outcome for the patient, especially at the dose selected for this indication. In addition, there were concerns on the thromboembolic side effects (excessive clotting) for this indication, but the number of patients treated was too small for the CHMP to be able to balance this risk against the potential benefit.

Therefore, at the time of the withdrawal, the CHMP's view was that the benefit had not been sufficiently demonstrated and did not outweigh the identified risks.

The letter from the company notifying the EMEA of the withdrawal of the application is available under the tab 'All documents'.

The company has informed the CHMP that the current clinical trial of NovoSeven in intracerebral haemorrhage will continue.

There are no consequences for NovoSeven's use in the indications for which it is already authorised, where the known benefit and risk remain unchanged.

Questions and answers on the withdrawal of the application for a change to the marketing authorisation for NovoSeven

Reference Number: EMEA/133892/2006

English (EN) (35.33 KB - PDF)

First published: 27/04/2006Last updated: 27/04/2006
View
Other languages (18)

español (ES) (33.85 KB - PDF)

First published: 27/04/2006Last updated: 27/04/2006
View

čeština (CS) (143.72 KB - PDF)

First published: 27/04/2006Last updated: 27/04/2006
View

dansk (DA) (38.5 KB - PDF)

First published: 27/04/2006Last updated: 27/04/2006
View

Deutsch (DE) (39.03 KB - PDF)

First published: 27/04/2006Last updated: 27/04/2006
View

eesti keel (ET) (38.48 KB - PDF)

First published: 27/04/2006Last updated: 27/04/2006
View

ελληνικά (EL) (154.35 KB - PDF)

First published: 27/04/2006Last updated: 27/04/2006
View

français (FR) (39.04 KB - PDF)

First published: 27/04/2006Last updated: 27/04/2006
View

italiano (IT) (38.83 KB - PDF)

First published: 27/04/2006Last updated: 27/04/2006
View

latviešu valoda (LV) (144.26 KB - PDF)

First published: 27/04/2006Last updated: 27/04/2006
View

lietuvių kalba (LT) (143.13 KB - PDF)

First published: 27/04/2006Last updated: 27/04/2006
View

magyar (HU) (137.22 KB - PDF)

First published: 27/04/2006Last updated: 27/04/2006
View

Nederlands (NL) (38.97 KB - PDF)

First published: 27/04/2006Last updated: 27/04/2006
View

polski (PL) (147.7 KB - PDF)

First published: 27/04/2006Last updated: 27/04/2006
View

português (PT) (38.63 KB - PDF)

First published: 27/04/2006Last updated: 27/04/2006
View

slovenčina (SK) (139.92 KB - PDF)

First published: 27/04/2006Last updated: 27/04/2006
View

slovenščina (SL) (133.86 KB - PDF)

First published: 27/04/2006Last updated: 27/04/2006
View

Suomi (FI) (38.48 KB - PDF)

First published: 27/04/2006Last updated: 27/04/2006
View

svenska (SV) (38.27 KB - PDF)

First published: 27/04/2006Last updated: 27/04/2006
View

Key facts

Name of medicine
NovoSeven
EMA product number
EMEA/H/C/000074
Active substance
eptacog alfa (activated)
International non-proprietary name (INN) or common name
eptacog alfa (activated)
Therapeutic area (MeSH)
  • Hemophilia B
  • Thrombasthenia
  • Factor VII Deficiency
  • Hemophilia A
Anatomical therapeutical chemical (ATC) code
B02BD08
Marketing authorisation holder
Novo Nordisk A/S
Date of issue of marketing authorisation valid throughout the European Union
23/02/1996
Date of withdrawal
03/04/2006

Documents

Withdrawal letter : NovoSeven

English (EN) (19.66 KB - PDF)

First published: 03/04/2006Last updated: 03/04/2006
View

Novo Nordisk withdraw their application to extend the marketing authorisation for NovoSeven

Reference Number: EMEA/123938/2006

English (EN) (29.91 KB - PDF)

First published: 06/04/2006Last updated: 06/04/2006
View

Related information on withdrawals

The question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the application at the time of the withdrawal, and includes a link to the company's formal withdrawal letter.

An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 90').

News on NovoSeven

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 April 2022
22/04/2022
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 October 2018
19/10/2018

More information on NovoSeven

  • NovoSeven
This page was last updated on 06/04/2006

Share this page

Back to top

Product emergency hotline

OUTSIDE WORKING HOURS

About us
What we do
Careers
Committees & working parties
Regulatory network
European experts
Languages
Frequently asked questions
Glossaries
About this website
Cookies
Website data protection notice
Data protection at EMA
Search tips
Access to documents
Contacts
Send a question
EMA Service Desk (system support)
Services and databases

European Medicines Agency
Domenico Scarlattilaan 6
1083 HS Amsterdam
The Netherlands

Tel: +31 (0)88 781 6000

How to find us
Postal address and deliveries
Business hours and holidays

  • RSS Feed
  • Bluesky
  • YouTube
  • LinkedIn
© 1995 - 2025 European Medicines Agency
European Union agencies network
An agency of the European Union